PulseAugur / Brief
EN
LIVE 23:50:14

Brief

last 24h
[2/2] 221 sources

Multi-source AI news clustered, deduplicated, and scored 0–100 across authority, cluster strength, headline signal, and time decay.

  1. RESEARCH · Forbes — Innovation English(EN) ·

    Inside Incyte’s $120 Million AI For Drug Development Deal

    Genesis Molecular AI has secured a significant partnership with Incyte, a global biotech company, valued at $120 million. This deal includes $80 million in upfront cash and a $40 million equity investment, with potential future milestone payments and royalties that could exceed $1 billion. Incyte will contribute its experimental data to train Genesis's foundation model, aiming to accelerate drug discovery in areas like oncology, hematology, and inflammation. This collaboration highlights a growing trend of AI drug discovery firms partnering with major pharmaceutical companies for funding and data. AI

    Inside Incyte’s $120 Million AI For Drug Development Deal

    IMPACT Accelerates AI's role in drug discovery, potentially reducing development time and cost for new therapies.

  2. SIGNIFICANT · Last Week in AI English(EN) · · [2 sources]

    LWiAI Podcast #245 - TML-Interaction, Claude For Legal, Sam Altman on Stand

    OpenAI has launched new voice intelligence features, including GPT Realtime 2 powered by GPT-5, offering real-time translation and transcription with an emphasis on reduced latency and larger context windows. Anthropic is expanding its vertical product offerings with Claude for Legal and increased availability through AWS, while also developing methods to train ethical reasoning in agents. Meanwhile, Thinking Machines has previewed a novel conversational system, though it remains inaccessible to the public. AI

    LWiAI Podcast #245 - TML-Interaction, Claude For Legal, Sam Altman on Stand

    IMPACT New voice features and specialized legal AI tools signal continued vertical integration and performance improvements in large language models.